Survodutide and Tirzepatide Interaction

Avoid
Mechanism-based 70% confidence

Survodutide and Tirzepatide have a potentially harmful interaction with 70% confidence. Both Survodutide and Tirzepatide activate GLP-1 receptors. Combining GLP-1 agonists significantly increases risk of severe GI side effects (nausea, vomiting, pancreatitis). Not recommended. Both compounds affect the gi tract and pancreas, so monitoring these systems is recommended.

Compound Profiles

Survodutide

Dual GLP-1/Glucagon Receptor Agonist | Weight Loss & Diabetes

Dual agonism: GLP-1R reduces appetite and slows gastric emptying; GCGR increases energy expenditure and hepatic fat oxidation. EC50 0.

Half-life: Approximately 6 days (109-115 hours) Typical dose: 0.6mg starting, titrate up to 3.6-6.0mg weekly weight loss, metabolic
glp1 receptor cardiotoxicinsulin disrupting
View full profile

Tirzepatide

Dual GIP/GLP-1 Receptor Agonist | Weight Loss & Diabetes

Dual agonist targeting both GIP and GLP-1 receptors, producing glucose-dependent insulin stimulation, delayed gastric emptying, glucagon suppression, and central satiety signaling via hypothalamic pathways..

Half-life: ~5 days (120 hours) Typical dose: 2.5mg starting, titrate up to 5-15mg weekly weight loss, metabolic
glp1 receptor teratogenic
View full profile

Combined Organ Load

GI Tract
low
Pancreas
low

Frequently Asked Questions

Can I take Survodutide with Tirzepatide?

Combining Survodutide with Tirzepatide is not recommended. Both Survodutide and Tirzepatide activate GLP-1 receptors. Combining GLP-1 agonists significantly increases risk of severe GI side effects (nausea, vomiting, pancreatitis). Not recommended.

Is Survodutide and Tirzepatide safe together?

This combination carries significant risk. Both Survodutide and Tirzepatide activate GLP-1 receptors. Combining GLP-1 agonists significantly increases risk of severe GI side effects (nausea, vomiting, pancreatitis). Not recommended. Consult a healthcare professional before combining.

What are the interactions between Survodutide and Tirzepatide?

Both Survodutide and Tirzepatide activate GLP-1 receptors. Combining GLP-1 agonists significantly increases risk of severe GI side effects (nausea, vomiting, pancreatitis). Not recommended. This assessment has 70% confidence and is inferred from pharmacological mechanism analysis.

How should I time Survodutide and Tirzepatide?

Survodutide has a half-life of Approximately 6 days (109-115 hours) and Tirzepatide has a half-life of ~5 days (120 hours). No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.

Check this pair in the full Interaction Checker Full comparison: Survodutide vs Tirzepatide

This interaction analysis is compiled from research literature and pharmacological mechanism data. This assessment is inferred from known mechanisms and may not reflect all real-world outcomes. Always consult a healthcare professional before combining compounds.